AC
DFTX

Aristides Capital’s Definium Therapeutics DFTX Stock Holding History

Aristides Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37,625
Closed -$82.8K – 217
2022
Q4 		$82.8K Buy
+37,625
New +$104K 0.04% 222

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Aristides Capital's DFTX Position: Q1 2023 in Review

Aristides Capital sold out of Definium Therapeutics (DFTX) in Q1 2023, closing a stake of 37,625 shares — an estimated $82.8K sold.

Aristides Capital first reported a position in DFTX in Q4 2022 and held it in 1 quarter. The position peaked at $82.8K in Q4 2022. 88 funds tracked by Wall St. Rank hold DFTX as of Q1 2023.

  • Aristides Capital reported no remaining Definium Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Aristides Capital sold 37,625 Definium Therapeutics shares in Q1 2023, an estimated $82.8K.
  • Aristides Capital first reported a position in Definium Therapeutics in Q4 2022 and held it in 1 quarter.
  • Aristides Capital's Definium Therapeutics position peaked at $82.8K in Q4 2022.
  • 88 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2023.

Based on Aristides Capital's 13F filing for Q1 2023, filed 12 May 2023.